89 results found.

Colorectal Cancer Metastatic Clinical Trial using TheraSphere

BTG International Inc. - Recruiting 18 years or older.
- A Phase III Clinical Trial Evaluating TheraSpherer in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy.
TheraSphere

Metastatic Colorectal Cancer, Metastatic Gastric Cancer, Metastat Clinical Trial using CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers.
CD8+ young TIL; Aldesleukin; Cyclophosphamide; Fludarabine

Colorectal Cancer Metastatic Clinical Trial using AFLIBERCEPT AVE0005; FOLFIRI

Sanofi - Recruiting 18 years or older.
- A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen.
AFLIBERCEPT AVE0005; FOLFIRI

Colorectal Cancer Clinical Trial using panitumumab; erlotinib hydrochloride; irinotecan hydrochloride

Northwestern University - Recruiting 18 years or older.
- A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer.
panitumumab; erlotinib hydrochloride; irinotecan hydrochloride

Colorectal Cancer Clinical Trial using bevacizumab; FOLFIRI regimen; mFOLFOX6

Genentech - Recruiting 18 years or older.
- A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer.
bevacizumab; FOLFIRI regimen; mFOLFOX6

Colorectal Neoplasms Clinical Trial using Regorafenib (BAY73- 4506)

Bayer - Recruiting 18 years or older.
- An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy.
Regorafenib (BAY73- 4506)

Metastatic Colorectal Cancer Clinical Trial using Metastases resection; Bevacizumab; 5 FU (5Fluorouracile); Oxaliplatine; Irinotecan

Cliniques universitaires Saint-Luc- Université Catholique de Louvain - Recruiting 18 years or older.
- Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI.
Metastases resection; Bevacizumab; 5 FU (5Fluorouracile); Oxaliplatine; Irinotecan

Metastatic Colorectal Cancer Clinical Trial using Metastases Resection; 5-Fluorouracile; leucovorin L; Oxaliplatin; Irinotecan; Cetuximab

Cliniques universitaires Saint-Luc- Université Catholique de Louvain - Recruiting 18 years or older.
- Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors.
Metastases Resection; 5-Fluorouracile; leucovorin L; Oxaliplatin; Irinotecan; Cetuximab

Solid Tumors, Melanoma, or Metastatic Colorectal Cancer Clinical Trial using CEP-32496

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2.
CEP-32496

Metastatic Colorectal Cancer Clinical Trial using FOLFOXIRI + Cetuximab; FOLFOXIRI

Sun Yat-sen University - Recruiting 18 years to 75 years.
- A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver.
FOLFOXIRI + Cetuximab; FOLFOXIRI

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, or Me Clinical Trial using Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT.
Topical Dapsone 5% Gel; Moisturizer; oral antibiotics

Colorectal Cancer Clinical Trial using pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles

VU University Medical Center - Recruiting 18 years or older.
- Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET.
pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles

Multi-organ Metastatic Colorectal Cancer Clinical Trial using XELOX regimen according to standard procedures; FOLFOX regimen according to standard procedures; Surgery; radiofrequency ablation (RFA); transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE); stereotactic body radiation therapy (SBRT); Bevacizumab; tumor biopsy

VU University Medical Center - Recruiting 18 years or older.
- A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone..
XELOX regimen according to standard procedures; FOLFOX regimen according to standard procedures; Surgery; radiofrequency ablation (RFA); transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE); stereotactic body radiation therapy (SBRT); Bevacizumab; tumor biopsy

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Metastatic Cancer, Metastatic Melanoma, Renal Cancer, Colorectal Clinical Trial using Anti-VEGFR2 CAR CD8 plus PBL; Cyclophosphamide; Aldesleukin; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes.
Anti-VEGFR2 CAR CD8 plus PBL; Cyclophosphamide; Aldesleukin; Fludarabine

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational Study of Avastin Plus 5-FU Based Chemotherapy as First Line Treatment for Chinese Patients With Metastatic Colorectal Cancer..

Colorectal Cancer Clinical Trial using bevacizumab [Avastin]; leucovorin; 5-fluorouracil; irinotecan; oxaliplatin; capecitabine [Xeloda]; fluoropyrimidine-based chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 75 years.
- STEAM (SEQUENTIAL TRIPLET AND AVASTIN MAINTENANCE): FOLFOXIRI/BEVACIZUMAB REGIMENS (CONCURRENT AND SEQUENTIAL) VS. FOLFOX/BEVACIZUMAB IN FIRST-LINE METASTATIC COLORECTAL CANCER.
bevacizumab [Avastin]; leucovorin; 5-fluorouracil; irinotecan; oxaliplatin; capecitabine [Xeloda]; fluoropyrimidine-based chemotherapy

Colon Cancer Clinical Trial using chemotherapy and GI-4000; GI-4000

Georgetown University - Recruiting 18 years or older.
- A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI in Patients With Newly Diagnosed Ras Mutant Positive Metastatic Colorectal Cancer or Patients With Ras Mutant Positive Colorectal Cancer Who Have Just Completed a First Line Therapy With an Oxaliplatin or Irinotecan Plus Fluoropyrimidine and Bevacizumab Containing Regimen.
chemotherapy and GI-4000; GI-4000

Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Adva Clinical Trial using FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Amgen - Recruiting 18 years or older.
- A Phase 2 Open Label Extension Study of Conatumumab and AMG 479.
FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Colorectal Cancers Clinical Trial using RENCA macrobeads

The Rogosin Institute - Recruiting 18 years or older.
- A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma.
RENCA macrobeads

Metastatic Colorectal Cancer Clinical Trial using Blood analysis by EPISPOT and Cellsearch

University Hospital, Montpellier - Recruiting 18 years or older.
- Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment.
Blood analysis by EPISPOT and Cellsearch

Colorectal Neoplasm Clinical Trial using Regorafenib (Stivarga, BAY 73-4506)

Bayer - Recruiting 18 years or older.
- RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy.
Regorafenib (Stivarga, BAY 73-4506)

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study of Avastinr First-line in Metastatic Colorectal Cancer (Koralle).

Metastatic Colorectal Cancer Clinical Trial using Xeloda

Samsung Medical Center - Recruiting 18 years or older.
- A Phase III Trial of XELOX (Xeloda/Oxaliplatin) Followed by Xeloda Maintenance Versus Best Supportive Care (BSC) in Metastatic Colorectal Cancer.
Xeloda

Metastatic Colorectal Cancer Clinical Trial using MEK162; Panitumumab

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer.
MEK162; Panitumumab

Metastatic Colorectal Cancer Clinical Trial using Cetuximab; Capecitabine

Swiss Group for Clinical Cancer Research - Recruiting 70 years or older.
- Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial.
Cetuximab; Capecitabine

Colorectal Cancer Clinical Trial using Folfox plus Bevacizumab and reolysin; Folfox plus Bevacizumab

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer..
Folfox plus Bevacizumab and reolysin; Folfox plus Bevacizumab

Colorectal Cancer Clinical Trial using GS-6624; FOLFIRI; Placebo to match GS-6624

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen..
GS-6624; FOLFIRI; Placebo to match GS-6624

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER.

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Bevacizumab in Combination With Standard Chemotherapy Regimens as First Line in Patients With Metastatic Cancer of the Colon or the Rectum.

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 75 years or older.
- Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin r Regimen for Metastatic Colorectal Cancer..

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 70 years or older.
- Prospective Non-interventional Study to Collect Data on the Use of Avastin and Conventional Chemotherapy for the Treatment of Previously Untreated Metastatic Colorectal Cancer in Patients >/= 70 Years.

Colorectal Cancer Clinical Trial using Cetuximab; Neratinib

National Surgical Adjuvant Breast and Bowel Project (NSABP) - Recruiting 18 years or older.
- A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With 'Quadruple Wild-Type' (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab.
Cetuximab; Neratinib

Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Can Clinical Trial using DCVax-Direct

Northwest Biotherapeutics - Recruiting 18 years to 75 years.
- A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS.
DCVax-Direct

Metastatic Colorectal Cancer Clinical Trial using aflibercept + FOLFIRI

CR-CSSS Champlain-Charles-Le Moyne - Recruiting 18 years or older.
- A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.
aflibercept + FOLFIRI

Colorectal Cancer Metastatic Clinical Trial using aflibercept AVE0005

Sanofi - Recruiting 20 years or older.
- A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen.
aflibercept AVE0005

Colorectal Cancer Metastatic, Liver Metastases, or KRAS Wild Type Clinical Trial using FOLFOX6; Bevacizumab; Panitumumab; Surgery

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 75 years.
- Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS Colorectal Cancer.
FOLFOX6; Bevacizumab; Panitumumab; Surgery

Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Clinical Trial using ziv-aflibercept; leucovorin calcium; irinotecan hydrochloride; fluorouracil

City of Hope Medical Center - Recruiting 18 years or older.
- A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer.
ziv-aflibercept; leucovorin calcium; irinotecan hydrochloride; fluorouracil

Metastatic Colorectal Cancer, Colon Cancer, or Rectal Cancer Clinical Trial using IMMU-130

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer..
IMMU-130

Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma (Skin), o Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer.

Colorectal Cancer Clinical Trial using bevacizumab [Avastin]; XELOX; mFOLFOX6; FOLFIRI

Hoffmann-La Roche - Recruiting 18 years or older.
- An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin) [ASCENT].
bevacizumab [Avastin]; XELOX; mFOLFOX6; FOLFIRI

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study).

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-interventional Multicenter Study of First-line Avastinr (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer.

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Colorectal Cancer Metastatic Clinical Trial using Regorafenib (BAY 73-4506); FOLFIRI; Placebo

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer.
Regorafenib (BAY 73-4506); FOLFIRI; Placebo

Pancreatic Cancer, or Colorectal Cancer Clinical Trial using Cancer macrobead placement in abdominal cavity

The Rogosin Institute - Recruiting 18 years or older.
- An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma.
Cancer macrobead placement in abdominal cavity

Colorectal Cancer Metastatic Clinical Trial using AFLIBERCEPT AVE0005; OXALIPLATIN; CAPECITABINE

Sanofi - Recruiting 18 years or older.
- A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient.
AFLIBERCEPT AVE0005; OXALIPLATIN; CAPECITABINE

Metastatic Colorectal Cancer, or EGFR-Expressing Metastatic CRC Clinical Trial using Sorafenib (Bay 43-9006); cetuximab; proteomic profiling; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; pharmacological study; biopsy

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC).
Sorafenib (Bay 43-9006); cetuximab; proteomic profiling; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; pharmacological study; biopsy

Metastatic Colorectal Cancer Clinical Trial using BKM120; Panitumumab

NCIC Clinical Trials Group - Recruiting 18 years or older.
- Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer..
BKM120; Panitumumab

Metastatic Colorectal Cancer Clinical Trial using combination panitumumab and vemurafenib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer.
combination panitumumab and vemurafenib

Colorectal Cancer Clinical Trial

Samsung Medical Center - Recruiting 18 years or older.
- .

Colorectal Neoplasms Clinical Trial using BAY73-4506_Regorafenib

Bayer - Recruiting N/A or older.
- Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer.
BAY73-4506_Regorafenib

Solid Tumours of Epithelial Origin, or Metastatic Colorectal Canc Clinical Trial using ColoAd1

PsiOxus Therapeutics Ltd - Recruiting 18 years or older.
- A Clinical Study Of ColoAd1 Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer.
ColoAd1

Colorectal Cancer Clinical Trial

Milton S. Hershey Medical Center - Recruiting 18 years or older.
- Prevalence of Stem Cell and Prognostic Markers in Circulating Tumor Cells of Patients With Metastatic Colorectal Cancer Undergoing Chemotherapy.

Metastatic Colorectal Cancer Clinical Trial

National Cancer Institute, Naples - Recruiting 18 years or older.
- Multicentered Observational Prospective Cohort Study on the Treatment of Metastatic Colorectal Cancer and the Role of Evaluating K-Ras.

Colorectal Cancer Metastatic Clinical Trial using Sorafenib Plus Capecitabine (SorCape)

University of Florida - Recruiting 18 years or older.
- Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer.
Sorafenib Plus Capecitabine (SorCape)

Colorectal Cancer Clinical Trial using Simvastatin

Samsung Medical Center - Recruiting 20 years or older.
- A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients.
Simvastatin

Colorectal Cancer, or Metastatic Cancer Clinical Trial using floxuridine; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis.
floxuridine; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Metastatic Breast Cancer, Colorectal Cancer, or Prostate Cancer Clinical Trial using Foxy-5

WntResearch AB - Recruiting 18 years or older.
- Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colorectal or Prostate Cancer.
Foxy-5

Colorectal Cancer Clinical Trial using NKTR-102; irinotecan

Nektar Therapeutics - Recruiting 18 years or older.
- A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naive, KRAS-Mutant, Metastatic Colorectal Cancer (mCRC).
NKTR-102; irinotecan

Metastatic Colorectal Cancer Clinical Trial using Aflibercept

Brown University - Recruiting 18 years or older.
- BrUOG C261:Single Agent Adjuvant Aflibercept for Patients With Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study.
Aflibercept

Colorectal Cancer Metastatic Clinical Trial using Aflibercept AVE0005; Placebo

Sanofi - Recruiting 18 years or older.
- A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen.
Aflibercept AVE0005; Placebo

Colorectal Cancer Clinical Trial using LGX818; Cetuximab; BYL719

Novartis - Recruiting 18 years or older.
- A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer.
LGX818; Cetuximab; BYL719

Colorectal Neoplasms, or Metastatic Disease Clinical Trial using Regorafenib

Spanish Cooperative Group for Digestive Tumour Therapy (TTD) - Recruiting 18 years or older.
- A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC).
Regorafenib

Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of Clinical Trial using panitumumab; irinotecan hydrochloride; fluorouracil; leucovorin calcium

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) Wild-Type Metastatic Colorectal Cancer..
panitumumab; irinotecan hydrochloride; fluorouracil; leucovorin calcium

Metastatic Colorectal Cancer Clinical Trial using FOLFOXIRI + Panitumumab; FOLFOXIRI

AIO-Studien-gGmbH - Recruiting 18 years or older.
- An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and K-ras Wild Type.
FOLFOXIRI + Panitumumab; FOLFOXIRI

Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Non-small-ce Clinical Trial using MORAb-066

Morphotek - Recruiting 18 years or older.
- A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies.
MORAb-066

Colorectal Cancer Clinical Trial using panitumumab; cyclosporine; irinotecan hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)].
panitumumab; cyclosporine; irinotecan hydrochloride

Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of Clinical Trial using Akt inhibitor MK2206; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation.
Akt inhibitor MK2206; laboratory biomarker analysis; pharmacological study

Metastatic Pancreatic Cancer, or Metastatic Colorectal Cancer Clinical Trial using NPC-1C/NEO-102

Precision Biologics, Inc - Recruiting 18 years to 85 years.
- A Phase 1/2A Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy.
NPC-1C/NEO-102

Metastatic Colorectal Cancer Patients Clinical Trial using Gemcitabine + Pemetrexed

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori - Recruiting 18 years or older.
- A Phase II Study to Evaluate Activity and Toxicity of Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients.
Gemcitabine + Pemetrexed

Colorectal Cancer, or Metastasis Clinical Trial using Bevacizumab + blood samples

Centre Leon Berard - Recruiting 18 years or older.
- Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab.
Bevacizumab + blood samples

Metastatic Colorectal Cancer Clinical Trial using fluorouracil/irinotecan/levo-folinic acid/bevacizumab

University of Rome Tor Vergata - Recruiting N/A or older.
- Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy.
fluorouracil/irinotecan/levo-folinic acid/bevacizumab

Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors Clinical Trial using Sorafenib and irinotecan combination; Sorafenib monotherapy; Irinotecan monotherapy

Centre Val d'Aurelle - Paul Lamarque - Recruiting 18 years or older.
- A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective.
Sorafenib and irinotecan combination; Sorafenib monotherapy; Irinotecan monotherapy

Colorectal Neoplasms, Neoplasm Metastasis, or Liver Neoplasms Clinical Trial using Cetuximab; chemotherapy of mFOLFOX6 or FOLFIRI

Fudan University - Recruiting 18 years to 75 years.
- Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer.
Cetuximab; chemotherapy of mFOLFOX6 or FOLFIRI

Metastatic Colorectal Cancer Clinical Trial

Institut National de la Sant‚ Et de la Recherche M‚dicale, France - Recruiting 18 years or older.
- Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : Effect of Chemotherapy on Cancerous Proliferation Based on the Dynamic Excretion of Urinary Nucleosides..

Metastatic Colorectal Cancer Clinical Trial using Perfusion CT scan

University of Oxford - Recruiting 18 years or older.
- Perfusion Computed Tomography Pilot Study in the NCRN FOXFIRE Clinical Trial to Determine Blood Flow to Liver Metastases.
Perfusion CT scan

Metastatic Colorectal Cancer Clinical Trial using Capecitabine; Bevacizumab; Irinotecan

University Hospital of Crete - Recruiting 18 years to 72 years.
- A Phase II Study of Irinotecan, Capecitabine and Avastin in Patients With Metastatic Colorectal Cancer, Who Have Progressed After 1ST Line Therapy With Folfox/Avastin..
Capecitabine; Bevacizumab; Irinotecan

Metastatic Colorectal Cancer Clinical Trial using Biomarker sampling

Helsinki University Central Hospital - Recruiting 18 years or older.
- A Population-based Prospective Study to Evaluate Clinical Behaviour, Resectability and Survival in 1st Line Metastatic Colorectal Cancer (CRC) Patients in Finland.
Biomarker sampling

Metastatic Colorectal Cancer Clinical Trial using Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

King Faisal Specialist Hospital & Research Center - Recruiting 14 years to 85 years.
- A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer.
Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Colorectal Carcinoma Clinical Trial using axitinib

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Assessment of the Tumor Vascular Effects of the Pan-vegfr Tyrosine Kinase Inhibitor Axitinib Using Dynamic Contrast-enhanced Ultrasonography (Dce-us) in Patients With Refractory Metastatic Colorectal Cancer.
axitinib

Colorectal Cancer Clinical Trial using bevacizumab; capecitabine; fluorouracil; irinotecan hydrochloride; diagnostic laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 80 years.
- Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma.
bevacizumab; capecitabine; fluorouracil; irinotecan hydrochloride; diagnostic laboratory biomarker analysis

Colorectal Cancer Clinical Trial using SB injection

SBPharmaceutical IND, Co., LTD - Recruiting 18 years or older.
- Phase ?,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Colorectal Cancer.
SB injection

Metastatic Colorectal Cancer Clinical Trial using AMG386 and bevacizumab

Austin Health - Recruiting N/A or older.
- Open Label Phase II Study Evaluating the Combination of Bevacizumab and AMG386 Without Chemotherapy as First Line Treatment of Advanced Colorectal Cancer.
AMG386 and bevacizumab

Colorectal Cancer Clinical Trial using FOLFIRI regimen; fluorouracil; irinotecan hydrochloride; leucovorin calcium; zibotentan; laboratory biomarker analysis; pharmacogenomic studies

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy.
FOLFIRI regimen; fluorouracil; irinotecan hydrochloride; leucovorin calcium; zibotentan; laboratory biomarker analysis; pharmacogenomic studies

Colorectal Cancer Clinical Trial using S-1, leucovorin, oxaliplatin

Peking University - Recruiting 20 years to 80 years.
- A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer.
S-1, leucovorin, oxaliplatin

Advanced Colorectal Cancer Clinical Trial using Nimotuzumab and chemotherapy

Peking University - Recruiting 18 years or older.
- Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras.
Nimotuzumab and chemotherapy

Colorectal Cancer Clinical Trial using bevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium

National Cancer Institute (NCI) - Recruiting 18 years to 74 years.
- Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study.
bevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium